Measuring the Impact of Real Time fMRI Neurofeedback in Borderline Personality Disorder
NCT ID: NCT04306341
Last Updated: 2023-05-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
3 participants
INTERVENTIONAL
2020-11-15
2022-10-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Mindfulness-based Neurofeedback to Augment Psychotherapy for Adults With Borderline Personality Disorder
NCT06446765
Training of Neural Responding in BPD
NCT02866110
A Neurofeedback Booster for Emotion Regulation Therapy
NCT04333888
Emotional Regulation and Impulsivity Among Adolescents with Borderline Personality Disorder
NCT03209102
Affect-based Impulsivity in Borderline Personality Disorder
NCT06880640
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental
Neurofeedback in conjunction with Dialectical Behavior Therapy
real time fMRI neurofeedback
Participants will use real time feedback about their amygdala activity to learn to decrease amygdala activity.
Control
Dialectical Behavior Therapy (treatment as usual)
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
real time fMRI neurofeedback
Participants will use real time feedback about their amygdala activity to learn to decrease amygdala activity.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. must meet specific clinical criteria
3. Inclusion in Experimental group requires participants meet standard safety and quality control requirements for MR scanning
4. For female participants, not pregnant and willing to use a reliable method of contraception during the study
Exclusion Criteria
2. vision problem not able to be corrected to normal range
3. medication changes w/in one month
4. Lifetime hx of schizophrenia, schizoaffective d/o, bipolar I disorder.
5. illicit substance use within 7 days of MRI scans
6. taking scheduled opiates
7. taking scheduled benzodiazepines
8. taking scheduled anti-histamines
9. history of seizures
10. significant current or past neurologic illness
11. BMI \< 16.5
18 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AE Foundation
OTHER
Central Institute of Mental Health, Mannheim
OTHER
Yale University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sarah K Fineberg, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Yale University
Michelle Hampson, PhD
Role: PRINCIPAL_INVESTIGATOR
Yale University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Connecticut Mental Health Center
New Haven, Connecticut, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2000026750
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.